Japan Approves 22 Drugs Including First IFN-Free Hep C Therapy
This article was originally published in PharmAsia News
Executive Summary
Japan approved 22 new drugs on July 4 including Daklinza (daclatasvir) 60mg tablets for the treatment of hepatitis C from Bristol-Myers Squibb.